{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:14:00Z","timestamp":1776928440742,"version":"3.51.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma GmbH, Nuremberg, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Migraine affects about 12% of the worldwide population causing substantial personal and societal burden. Yet, migraine remains underdiagnosed and untreated. EPISCOPE was a web-based survey among a German migraine patient cohort to characterize the medical care and prophylactic treatment status aiming to identify unmet needs. Potential migraine patients were identified via an ID Migraine screener. Their socioeconomic background, medical care experience, acute medication use, as well as use and experience of migraine prophylaxis was assessed by a questionnaire. Data of 29,011 participants was collected. 21,504 participants were identified as migraine patients. Patients with a higher number of monthly migraine days experienced better medical care. However, even among chronic migraine patients, 54% were not consulting a physician, 30% did not feel well-informed about medication overuse and 48% had never tried prophylactic migraine treatment. Among patients receiving prophylactic migraine treatment, up to 33% were not satisfied with their prophylaxis due to insufficient efficacy. Taken together, EPISCOPE describes the largest German migraine patient cohort so far. The survey provides detailed and valuable insight into the current medical care and prophylactic treatment situation in a highly developed European country and identifies reasons why the medical care of migraine patients is still insufficient.<\/jats:p>","DOI":"10.1038\/s41598-022-08716-w","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T11:04:45Z","timestamp":1647515085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Results of the gErman migraine PatIent Survey on medical Care and prOPhylactic treatment Experience (EPISCOPE)"],"prefix":"10.1038","volume":"12","author":[{"given":"Marie","family":"Groth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaza","family":"Katsarava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ehrlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"8716_CR1","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse, D. C. et al. Life with migraine: Effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 59, 1286\u20131299. https:\/\/doi.org\/10.1111\/head.13613 (2019).","journal-title":"Headache"},{"key":"8716_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-018-0839-1","volume":"19","author":"Z Katsarava","year":"2018","unstructured":"Katsarava, Z., Mania, M., Lampl, C., Herberhold, J. & Steiner, T. J. Poor medical care for people with migraine in Europe\u2014Evidence from the Eurolight study. J. Headache Pain 19, 10. https:\/\/doi.org\/10.1186\/s10194-018-0839-1 (2018).","journal-title":"J. Headache Pain"},{"key":"8716_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11916-011-0233-z","volume":"16","author":"Z Katsarava","year":"2012","unstructured":"Katsarava, Z., Buse, D. C., Manack, A. N. & Lipton, R. B. Defining the differences between episodic migraine and chronic migraine. Curr. Pain Headache Rep. 16, 86\u201392. https:\/\/doi.org\/10.1007\/s11916-011-0233-z (2012).","journal-title":"Curr. Pain Headache Rep."},{"key":"8716_CR4","unstructured":"WHO & Burden, L. T. Atlas of headache disorders and resources in the world 2011. (2011)."},{"key":"8716_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10194-012-0425-x","volume":"13","author":"MS Yoon","year":"2012","unstructured":"Yoon, M. S. et al. Prevalence of primary headaches in Germany: results of the German Headache Consortium Study. J. Headache Pain 13, 215\u2013223. https:\/\/doi.org\/10.1007\/s10194-012-0425-x (2012).","journal-title":"J. Headache Pain"},{"key":"8716_CR6","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/head.12878","volume":"56","author":"RB Lipton","year":"2016","unstructured":"Lipton, R. B., Manack Adams, A., Buse, D. C., Fanning, K. M. & Reed, M. L. A comparison of the chronic migraine epidemiology and outcomes (CaMEO) study and American Migraine Prevalence and Prevention (AMPP) study: Demographics and headache-related disability. Headache 56, 1280\u20131289. https:\/\/doi.org\/10.1111\/head.12878 (2016).","journal-title":"Headache"},{"key":"8716_CR7","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter, U. et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392, 2280\u20132287. https:\/\/doi.org\/10.1016\/S0140-6736(18)32534-0 (2018).","journal-title":"Lancet"},{"key":"8716_CR8","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby, P. J. et al. A controlled trial of erenumab for episodic migraine. N. Engl. J. Med. 377, 2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa1705848 (2017).","journal-title":"N. Engl. J. Med."},{"key":"8716_CR9","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick, D. W. et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38, 1026\u20131037. https:\/\/doi.org\/10.1177\/0333102418759786 (2018).","journal-title":"Cephalalgia"},{"key":"8716_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-018-0946-z","volume":"19","author":"P Martelletti","year":"2018","unstructured":"Martelletti, P. et al. My migraine voice survey: A global study of disease burden among individuals with migraine for whom preventive treatments have failed. J. Headache Pain 19, 115. https:\/\/doi.org\/10.1186\/s10194-018-0946-z (2018).","journal-title":"J. Headache Pain"},{"key":"8716_CR11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1177\/0333102412454945","volume":"32","author":"A Radtke","year":"2012","unstructured":"Radtke, A. & Neuhauser, H. Low rate of self-awareness and medical recognition of migraine in Germany. Cephalalgia 32, 1023\u20131030. https:\/\/doi.org\/10.1177\/0333102412454945 (2012).","journal-title":"Cephalalgia"},{"key":"8716_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1526-4610.2006.00430.x","volume":"46","author":"C Lucas","year":"2006","unstructured":"Lucas, C., Geraud, G., Valade, D., Chautard, M. H. & Lanteri-Minet, M. Recognition and therapeutic management of migraine in 2004, in France: Results of FRAMIG 3, a French nationwide population-based survey. Headache 46, 715\u2013725. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00430.x (2006).","journal-title":"Headache"},{"key":"8716_CR13","doi-asserted-by":"publisher","first-page":"e54074","DOI":"10.1371\/journal.pone.0054074","volume":"8","author":"WB Young","year":"2013","unstructured":"Young, W. B., Park, J. E., Tian, I. X. & Kempner, J. The stigma of migraine. PLoS ONE 8, e54074. https:\/\/doi.org\/10.1371\/journal.pone.0054074 (2013).","journal-title":"PLoS ONE"},{"key":"8716_CR14","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/j.1468-2982.2006.01186.x","volume":"26","author":"I Kavuk","year":"2006","unstructured":"Kavuk, I. et al. One-year prevalence and socio-cultural aspects of chronic headache in Turkish immigrants and German natives. Cephalalgia 26, 1177\u20131181. https:\/\/doi.org\/10.1111\/j.1468-2982.2006.01186.x (2006).","journal-title":"Cephalalgia"},{"key":"8716_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s10194-019-0970-7","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner, T. J. et al. Headache service quality: The role of specialized headache centres within structured headache services, and suggested standards and criteria as centres of excellence. J. Headache Pain 20, 24. https:\/\/doi.org\/10.1186\/s10194-019-0970-7 (2019).","journal-title":"J. Headache Pain"},{"key":"8716_CR16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.mayocp.2015.01.010","volume":"90","author":"AJ Starling","year":"2015","unstructured":"Starling, A. J. & Dodick, D. W. Best practices for patients with chronic migraine: Burden, diagnosis, and management in primary care. Mayo Clin. Proc. 90, 408\u2013414. https:\/\/doi.org\/10.1016\/j.mayocp.2015.01.010 (2015).","journal-title":"Mayo Clin. Proc."},{"key":"8716_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.7861\/clinmedicine.15-4-344","volume":"15","author":"HC Diener","year":"2015","unstructured":"Diener, H. C., Solbach, K., Holle, D. & Gaul, C. Integrated care for chronic migraine patients: Epidemiology, burden, diagnosis and treatment options. Clin. Med. (Lond.) 15, 344\u2013350. https:\/\/doi.org\/10.7861\/clinmedicine.15-4-344 (2015).","journal-title":"Clin. Med. (Lond.)"},{"key":"8716_CR18","unstructured":"Diener, H.-C., Gaul, C., Kropp, P. et al., Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne, S1-Leitlinie. Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie (2018)."},{"key":"8716_CR19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp, Z. et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. Cephalalgia 37, 470\u2013485. https:\/\/doi.org\/10.1177\/0333102416678382 (2017).","journal-title":"Cephalalgia"},{"key":"8716_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1212\/01.wnl.0000078940.53438.83","volume":"61","author":"RB Lipton","year":"2003","unstructured":"Lipton, R. B. et al. A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology 61, 375\u2013382. https:\/\/doi.org\/10.1212\/01.wnl.0000078940.53438.83 (2003).","journal-title":"Neurology"},{"key":"8716_CR21","doi-asserted-by":"publisher","first-page":"251581632096277","DOI":"10.1177\/2515816320962773","volume":"3","author":"A Thiele","year":"2020","unstructured":"Thiele, A., Strau\u00df, S., Angermaier, A., Kronenbuerger, M. & Fleischmann, R. Translation and validation of an extended German version of ID Migraine\u2122 as a migraine screening tool. Cephalalgia Rep. 3, 2515816320962773. https:\/\/doi.org\/10.1177\/2515816320962773 (2020).","journal-title":"Cephalalgia Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08716-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08716-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08716-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:11:35Z","timestamp":1669335095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08716-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8716"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-08716-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"28 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ZK received research funding from Novartis. He received consultation fees from Allergan, Daiichi, Lilly, Lundbeck, Merck, Novartis, TEVA. None of them were related to this work. MG and ME are Novartis employees.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4589"}}